Activation mechanism of coronavirus membrane fusion protein

Grant number: 20K07519

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $41,106
  • Funder

    KAKENHI
  • Principal Investigator

    Matsuyama Shutoku Unspecified
  • Research Location

    Japan
  • Lead Research Institution

    National Institute of Infectious Diseases
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Biochemical analysis of packing and assembling heptad repeat motifs in the coronavirus spike protein trimer.

Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide.

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.

The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.